Alzheimer’s Disease: Can Cannabis Slow the Cognitive Decline?

Alzheimer’s disease is a progressive neurodegenerative disorder that is characterized by a decline in cognitive function and the ability to perform everyday activities. As the disease advances, individuals may experience memory loss, language problems, disorientation, mood swings, and behavior issues. Despite significant research efforts, Alzheimer’s disease remains incurable, leading scientists to explore alternative treatments, including the use of medical cannabis.

The Neuroprotective Properties of Cannabinoids

Cannabinoids are compounds found in the cannabis plant, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most researched. These compounds interact with the body’s endocannabinoid system, which plays a role in maintaining biological harmony in response to environmental changes. The neuroprotective properties of cannabinoids have garnered attention for their potential to support brain health.

Cannabinoids and Brain Health

Research suggests that cannabinoids have antioxidant properties and the ability to reduce inflammation in the brain, which are two significant contributors to Alzheimer’s disease. A study published in the “Journal of Alzheimer’s Disease” posited that cannabinoids could aid in the removal of the toxic amyloid beta protein, which forms clumps in the brains of Alzheimer’s patients and is a hallmark of the disease (Cao et al., 2014).

Moreover, cannabinoids may support the growth and development of brain cells. A review in “Frontiers in Pharmacology” highlights that the activation of cannabinoid receptors could promote neurogenesis, or the growth of new brain cells, in the adult brain (Gowran et al., 2011).

Cannabis and Symptom Management in Alzheimer’s

Apart from potential disease-modifying effects, cannabis may also help manage symptoms associated with Alzheimer’s. These include agitation, aggression, and insomnia. A study in “The American Journal of Geriatric Psychiatry” showed that THC could reduce these symptoms and was associated with decreased severity and frequency of delusions, agitation/aggression, irritability, apathy, and sleep (Shelef et al., 2016).

Cautions and Current Research Stance

While the data on cannabis use in Alzheimer’s disease is promising, it is still not conclusive. Cannabis use can have potential side effects, such as impaired short-term memory, altered judgment, and in high doses, it can exacerbate or induce cognitive impairments, especially in the elderly. It is also crucial to note that most current research relies heavily on animal models or small-scale human studies.

Medical professionals are therefore cautious and do not universally recommend cannabis as a treatment for Alzheimer’s. Ongoing research aims to provide a clearer understanding of how cannabinoids may be used safely and effectively in this context.


Current evidence indicates that cannabis has potential neuroprotective properties that could be beneficial in slowing the progression of Alzheimer’s disease and managing some of its symptoms. However, more research is needed to fully understand its efficacy and safety, particularly in the elderly population that is most affected by Alzheimer’s disease.

For individuals considering the use of medical cannabis for Alzheimer’s disease, it is essential to consult with healthcare providers to evaluate the potential benefits and risks. As science advances, we may discover more definitive answers on how cannabinoids can be integrated into Alzheimer’s treatment regimens.


  1. Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., … & Cai, J. (2014). The potential therapeutic effects of THC on Alzheimer’s disease. Journal of Alzheimer’s Disease, 42(3), 973-984.
  2. Gowran, A., Noonan, J., & Campbell, V. A. (2011). The multiplicity of action of cannabinoids: implications for treating neurodegeneration. Frontiers in Pharmacology, 2, 76.
  3. Shelef, A., Barak, Y., Berger, U., Paleacu, D., Tadger, S., Plopsky, I., & Baruch, Y. (2016). Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. The American Journal of Geriatric Psychiatry, 24(3), 212-219.

This blog post is for informational purposes only and does not constitute medical advice. It is important to consult with healthcare professionals before starting any new treatment.


Recent Post

Skip the Line and Order Online

Follow Us On

Subscribe to Our Newsletter.

We need to verify your age.

Sorry, you cannot proceed further.

We’re sorry, but you must be at least 18 years old to access the content and products on Botanical Sciences. It’s important to us to adhere to legal guidelines for the sale and promotion of cannabis-based products.

Thank you for your understanding.

We need to verify your age.

Are you 18 years or older?

Cannabis products are for use only by individuals who are at least 18 years old. Please confirm your age to continue.